Trials / Completed
CompletedNCT00034203
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether a humanized monoclonal antibody (efalizumab) is safe and effective in the treatment of rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | efalizumab |
Timeline
- Start date
- 2002-04-01
- Completion
- 2003-08-01
- First posted
- 2002-04-25
- Last updated
- 2005-06-24
Locations
52 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00034203. Inclusion in this directory is not an endorsement.